Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy
1
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Cytomegalovirus (CMV) surveillance and preemptive therapy is a widely-used strategy for preventing CMV disease in transplant recipients. However, there are limited data on the incidence and patterns of CMV disease during the preemptive period. Thus, we investigated the incidence and pattern of tissue-invasive CMV disease in CMV seropositive kidney transplantation (KT) and hematopoietic stem cell transplantation (HCT) recipients during preemptive therapy. Methods: We prospectively identified patients with tissue-invasive CMV disease among 664 KT (90%) and 496 HCT (96%) recipients who were D+/R+ (both donor and recipient seropositive) during a 4-year period. Results: The incidence rates of CMV disease were 4.1/100 person-years (4%, 27/664) in KT recipients and 5.0/100 person-years (4%, 21/496) in HCT recipients. Twenty-six (96%) of the KT recipients with CMV disease had gastrointestinal CMV, whereas 17 (81%) of the HCT recipients had gastrointestinal CMV and 4 (19%) had CMV retinitis. Thus, CMV retinitis was more common among HCT recipients (p = 0.03). All 27 KT recipients with CMV disease suffered abrupt onset of CMV disease before or during preemptive therapy; 10 (48%) of the 21 HCT recipients with CMV disease were also classified in this way but the other 11 (52%) were classified as CMV disease following successful ganciclovir preemptive therapy (p < 0.001). Conclusions: The incidence of CMV disease was about 4% in both KT and HCT recipients during preemptive therapy. However, CMV retinitis and CMV disease as a relapsed infection were more frequently found among HCT recipients.
Abstract
Background/Aims: Cytomegalovirus (CMV) surveillance and preemptive therapy is a widely-used strategy for preventing CMV disease in transplant recipients. However, there are limited data on the incidence and patterns of CMV disease during the preemptive period. Thus, we investigated the incidence and pattern of tissue-invasive CMV disease in CMV seropositive kidney transplantation (KT) and hematopoietic stem cell transplantation (HCT) recipients during preemptive therapy. Methods: We prospectively identified patients with tissue-invasive CMV disease among 664 KT (90%) and 496 HCT (96%) recipients who were D+/R+ (both donor and recipient seropositive) during a 4-year period. Results: The incidence rates of CMV disease were 4.1/100 person-years (4%, 27/664) in KT recipients and 5.0/100 person-years (4%, 21/496) in HCT recipients. Twenty-six (96%) of the KT recipients with CMV disease had gastrointestinal CMV, whereas 17 (81%) of the HCT recipients had gastrointestinal CMV and 4 (19%) had CMV retinitis. Thus, CMV retinitis was more common among HCT recipients (p = 0.03). All 27 KT recipients with CMV disease suffered abrupt onset of CMV disease before or during preemptive therapy; 10 (48%) of the 21 HCT recipients with CMV disease were also classified in this way but the other 11 (52%) were classified as CMV disease following successful ganciclovir preemptive therapy (p < 0.001). Conclusions: The incidence of CMV disease was about 4% in both KT and HCT recipients during preemptive therapy. However, CMV retinitis and CMV disease as a relapsed infection were more frequently found among HCT recipients.
참고문헌 (29)
- Razonable RR, "Cytomegalovirus in solid organ transplantation", Am J Transplant, 13(Suppl 4), pp.93~106 (2013)
- Boeckh M, "Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies", Biol Blood Marrow Transplant, 9, pp.543~558 (2003)
- Le Page AK, "International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines", Transplantation, 95, pp.1455~1460 (2013)
- Avery RK, "A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy", Bone Marrow Transplant, 26, pp.763~767 (2000)
- Han JS, "A survey on the cytomegalovirus antibodies in blood donors and the diseased", Korean J Blood Transfus, 1, pp.21~34 (1990)
- Khoury JA, "Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients", Am J Transplant, 6, pp.2134~2143 (2006)
- Reischig T, "Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation", Am J Transplant, 8, pp.69~77 (2008)
- Jung GO, "The effect of cytomegalovirus antigenemia titer on the efficacy of preemptive therapy for the prevention of cytomegalovirus disease after kidney transplantation", Transplant Proc, 42, pp.804~810 (2010)
- Green ML, "Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation", Biol Blood Marrow Transplant, 18, pp.1687~1699 (2012)
- Mori T, "Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation", Bone Marrow Transplant, 33, pp.431~434 (2004)
- Burns LJ, "Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation", Bone Marrow Transplant, 30, pp.945~951 (2002)
- Schetelig J, "Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia", Bone Marrow Transplant, 32, pp.695~701 (2003)
- Ozdemir E, "Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells", Blood, 100, pp.3690~3697 (2002)
- Hambach L, "Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation", Bone Marrow Transplant, 29, pp.903~906 (2002)
- Ko GB, "Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation", Transpl Infect Dis, 15, pp.416~423 (2013)
- 김탁, "신장이식 환자에서 HCMV 항원혈증 검사의 임상적 유용성", Infection and Chemotherapy, 41(2), pp.72~77 (2009), 대한감염학회
- Park SY, "Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study", J Antimicrob Chemother, 67, pp.1486~1492 (2012)
- Jang EY, "Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease", Clin Infect Dis, 48, pp.e121~e124 (2009)
- Moon SM, "Diagnostic yield of the cytomegalovirus (CMV) antigenemia assay and clinical features in solid organ transplant recipients and hematopoietic stem cell transplant recipients with CMV pneumonia", Transpl Infect Dis, 14, pp.192~197 (2012)
- Couzi L, "Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction", Transplant Proc, 44, pp.2809~2813 (2012)
- Poornima Ramanan, "Cytomegalovirus Infections in Solid Organ Transplantation: A Review", Infection and Chemotherapy, 45(3), pp.260~271 (2013), 대한감염학회
- Greiner M, "A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation", Infection, 40, pp.669~675 (2012)
- Li CR, "Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis", Blood, 83, pp.1971~1979 (1994)
- Tey SK, "Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications", PLoS One, 8, pp.e74744~ (2013)
- Egli A, "State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician", Clin Infect Dis, 55, pp.1678~1689 (2012)
- Durand CM, "Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients", Clin Infect Dis, 57, pp.1550~1559 (2013)
- Jacobson MA, "Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment", Ann Intern Med, 108, pp.585~594 (1988)
- Moore RD, "Natural history of opportunistic disease in an HIV-infected urban clinical cohort", Ann Intern Med, 124, pp.633~642 (1996)
- Cariani E, "Relationship between pp65 antigenemia levels and real-time quantitative DNA PCR for human cytomegalovirus (HCMV) management in immunocompromised patients", BMC Infect Dis, 7, pp.138~ (2007)